Pro-inflammatory cytokines – expression and release

Pro-inflammatory cytokines – expression and release refers to the biological process of synthesizing and secreting signaling proteins that drive the inflammatory response. Key molecules involved in this process include Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 beta (IL-1β), and Interleukin-6 (IL-6) (Dinarello, 2000, Chest). These cytokines are primarily produced by innate immune cells like macrophages and dendritic cells upon the activation of pattern recognition receptors (Zhang & An, 2007, Int Anesthesiol Clin). The expression is largely controlled by the NF-κB and MAPK signaling pathways, while release can be mediated through the classical secretory pathway or via inflammasome activation (Liu et al., 2017, Sig Transduct Target Ther). Dysregulation of this process is a central feature of autoimmune diseases, chronic inflammation, and acute conditions like cytokine storm (Fajgenbaum & June, 2020, NEJM). Therapeutic strategies include neutralizing these cytokines with monoclonal antibodies, blocking their receptors, or inhibiting the upstream signaling kinases that drive their expression (Feldmann & Maini, 2003, Nat Med). While these treatments are effective, they often lead to systemic immunosuppression and increased risk of infection. Monitoring efficacy typically involves measuring systemic levels of these cytokines or downstream markers like C-reactive protein.

Other names

Cytokine productionCytokine secretionPro-inflammatory mediator releaseCytokine synthesisInflammatory cytokine expression

Drugs modulate this process by inhibiting intracellular signaling pathways (e.g., JAK/STAT, NF-κB) to prevent cytokine transcription, blocking cytokine receptors to halt signal transduction, or using monoclonal antibodies to bind and neutralize the cytokines in the extracellular space.